Supersaturated Oxygen Delivery & Acute MI: Current Evidence, Practical Issues, and Future Research

Acute myocardial infarction is a significant global health issue, with a high mortality rate. Early intervention, specifically coronary angiography, has been shown to improve patient outcomes significantly. Recent technological advances have introduced novel therapeutic interventions like Supersaturated Oxygen (SSO₂) Therapy, which promises enhanced recovery post-ischemia. To evaluate the efficacy and potential benefits of SSO₂ therapy in improving post-ischemic outcomes, including left ventricular function, myocardial scarring, and overall cardiac morphology.

This review synthesizes findings from early clinical trials and pre-clinical animal studies focusing on the application of SSO₂. The therapy involves delivering oxygen at ten times the normal level directly to the infarcted artery to facilitate high oxygen diffusion before restoring downstream flow.

Pre-clinical studies demonstrate that SSO₂ therapy enhances Left ventricular ejection fraction (LVEF), increases mean arterial PaO2, reduces myocardial apoptosis, and decreases myocardial scarring and infarct sizes. Clinical trials, including the Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT I and AMIHOT II), have shown improvements in echocardiographic regional wall motion and have helped in preventing myocardial dilatation and remodeling.

SSO₂ therapy presents a promising advance in the treatment of myocardial infarction. While early results are favorable, indicating significant improvements in cardiac function and tissue preservation, long-term follow-up studies are necessary to determine the impact on mortality rates, recurrence of ischemic events, and healthcare resource utilization.